Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
AMD$518.01+51.58(+11.06%)AMD Reports Third Quarter 2026 Financial Results4:15:00 PM ETUNH$404.44+4.06(+1.01%)3 High Conviction Stocks + Charitable Giving: Tax Alpha With Raul Shah4:12:00 PM ETGOOG$278.42+0.49(+0.17%)Alphabet's Free Cash Flow Just Turned Negative. Should Investors Sell the Stock Now?4:09:00 PM ETPLTR$174.96-0.54(-0.31%)Hiding inside Palantir's skyrocketing quarter is a foreboding signal4:05:55 PM ETADI$420.98+8.11(+1.96%)Analog Devices Completes Acquisition of Alif Semiconductor Analog Devices, Inc. (NASDAQ: ADI) today announced the completion of its acquisition of Alif Semiconductor. The combination of ADI's leadership...4:05:00 PM ETANET$183.86+19.74(+12.03%)Arista Networks, Inc. Reports Third Quarter 2026 Financial Results4:05:00 PM ETCSCO$103.11+1.53(+1.51%)Cisco Schedules Conference Call for Q1 Fiscal Year 2027 Financial Results Cisco (NASDAQ: CSCO) has scheduled a conference call for Thursday, Nov 12, 2026, at 1:30 PM (PT); 4:30 PM (ET) to announce its first quarter fiscal...4:05:00 PM ETAMGN$454.10-11.28(-2.42%)Amgen third quarter sales rise 8%, led by cholesterol, cancer drugs4:04:22 PM ETGOOG$278.42+0.49(+0.17%)Anthropic's IPO is a high-stakes referendum on Big Tech — and this chart proves it4:04:00 PM ETAMGN$454.10-11.28(-2.42%)BRIEF-Amgen Q3 Adjusted Operating Expenses USD 5,689 Million4:03:48 PM ETPLTR$174.96-0.54(-0.31%)Palantir Stock: Buy, Hold or Sell After 96% Revenue Growth?4:01:03 PM ETAMGN$454.10-11.28(-2.42%)AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2026. "Amgen delivered another strong quarter as our strategy for...4:01:00 PM ETPLTR$174.96-0.54(-0.31%)How PLTR Earnings Show AI Sustainability Ramp, Adoption Rate Key Question4:00:29 PM ETNVDA$209.25+1.46(+0.70%)Nvidia vs. SK Hynix: Comparing Quarterly Revenue Trajectories3:56:43 PM ETMRNA$228.10-2.18(-0.95%)Moderna's Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success3:52:01 PM ETETR$108.92-0.94(-0.86%)4 Companies Just Raised Their Dividends. Which Payout Has the Most Room to Grow?3:47:45 PM ETPLTR$174.96-0.54(-0.31%)Palantir's Report Moved My Buy Price for the Stock. Here's the New Number.3:47:01 PM ETGOOG$278.42+0.49(+0.17%)ChatGPT's search volume is now roughly 20% of Google's. Wow, people were really sick of Google, huh?3:45:10 PM ETHD$334.00+2.07(+0.62%)Home Depot Has Raised Its Dividend 17 Straight Years. Here's What $10,000 Invested Pays Annually.3:45:00 PM ETNVDA$209.25+1.46(+0.70%)While the Rest of the Market Focuses on the Anthropic IPO, These Are My Top 2 Stocks to Buy in November3:44:00 PM ETAMD$518.01+51.58(+11.06%)AMD has been crushed into earnings. Here's one way to trade it3:40:51 PM ETMETA$621.27-0.97(-0.16%)META Q3 Earnings Call Put Spotlight on Muse Growth and AI Spending3:35:52 PM ETAAPL$330.34-1.57(-0.47%)Apple: The Midterms Won't Save It3:30:38 PM ETAMZN$250.30-0.80(-0.32%)Amazon rewrites its software engineering playbook for an era when AI writes the code3:26:54 PM ET

RYTM · NASDAQ

Rhythm Pharmaceuticals, Inc.

$86.44 -7.16 (-7.65%)

Company overview

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor agonist for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$6B
Employees
283
Headquarters
Boston, MA
Website
rhythmtx.com
CEO
David Meeker
Listed
October 9, 2017
P/E
-27.62
Dividend yield
0.00%

Company financials

Revenue
$217M
Gross profit
$194M
Operating income
-$197M
EBITDA
-$183M
Net income
-$203M
EPS
-$3.13
Total assets
$442M
Total debt
$227M
Gross margin
89.41%
Net margin
-93.33%
Earnings yield
-3.62%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

77.7988.6899.58110.47121.36
RYTM 1D NASDAQ O93.13H95.35L92.40C93.44+0.87 (+0.94%)Vol2.00M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
RYTMRhythm Pharmaceuticals, Inc. Stock news Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2026 Earnings Call Transcript Seeking Alpha
RYTMRhythm Pharmaceuticals, Inc. Stock news Rhythm Pharmaceuticals Q3 Earnings Call Highlights MarketBeat
RYTMRhythm Pharmaceuticals, Inc. Stock news Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue Estimates Zacks Investment Research
RYTMRhythm Pharmaceuticals, Inc. Stock news Rhythm Pharma Q3 net loss narrower than estimated on IMCIVREE demand Reuters
RYTMRhythm Pharmaceuticals, Inc. Stock news BRIEF-Rhythm Pharmaceuticals Q3 Net Income USD -41.369 Million Vs. IBES Estimate USD -50.1 Million Reuters
RYTMRhythm Pharmaceuticals, Inc. Press release Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update GlobeNewswire
RYTMRhythm Pharmaceuticals, Inc. Press release Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement GlobeNewswire
RYTMRhythm Pharmaceuticals, Inc. Stock news Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks Investment Research
RYTMRhythm Pharmaceuticals, Inc. Press release Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026 GlobeNewswire
RYTMRhythm Pharmaceuticals, Inc. Press release Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity GlobeNewswire
RYTMRhythm Pharmaceuticals, Inc. Stock news Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know Zacks Investment Research
RYTMRhythm Pharmaceuticals, Inc. Legal Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm PRNewsWire
RYTMRhythm Pharmaceuticals, Inc. Press release Rhythm Pharmaceuticals Announces Health Canada Approval of GlobeNewswire
RYTMRhythm Pharmaceuticals, Inc. Stock news Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 5.3% on Insider Selling Defense World
RYTMRhythm Pharmaceuticals, Inc. Stock news Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
RYTMRhythm Pharmaceuticals, Inc. Press release Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting GlobeNewswire
RYTMRhythm Pharmaceuticals, Inc. Press release Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer GlobeNewswire
RYTMRhythm Pharmaceuticals, Inc. Stock news Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday? Benzinga
RYTMRhythm Pharmaceuticals, Inc. Stock news Rhythm Pharmaceuticals Q2 Earnings Call Highlights Defense World
RYTMRhythm Pharmaceuticals, Inc. Press release Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences GlobeNewswire
See more
FAQ

Questions about Rhythm Pharmaceuticals, Inc.

What does Rhythm Pharmaceuticals, Inc. do?
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor agonist for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc.
What is RYTM's market cap?
Rhythm Pharmaceuticals, Inc. (RYTM) is a listed stock with a live quote. The latest market cap on this page is $6B.
Where is Rhythm Pharmaceuticals, Inc. headquartered?
Rhythm Pharmaceuticals, Inc. is headquartered in Boston, MA.
How do I get RYTM news from the API?
Call GET /v1/news?tickers=RYTM. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does RYTM news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for RYTM, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the RYTM price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs